CP-467688 is a retinal toxicant with a basic pKa=8.1 and lipophilic clogP=5.0. CP-467688 is promising for research of drug-induced retinopathy.

CP-457493 is an Erlotinib metabolite. CP-457493 can be detected in plasma.

Copanlisib-NH is a PI3Kα/δ ligand. Copanlisib-NH can be used as a ligand for target protein for PROTAC to develop and design degraders of PROTAC PI3Kα/δ, such as PROTAC PI3Kα/δ degrader-1. Copanlisib-NH can be used in breast cancer research.

Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals.

CN016 is a neuroprotective agent. CN016 inhibits the elevation of pro-inflammatory cytokines G-CSF, GM-CSF and IL-6 induced by Oxaliplatin. CN016 suppresses Paclitaxel-induced inflammatory responses and immune cell infiltration into sensory neurons. CN016 protects neurons from Paclitaxel-induced neurotoxic damage. CN016 protects mice against Oxaliplatin-induced peripheral neuropathy.

Clofilium phosphate (LY 150378) is an antiarrhythmic/antifibrillatory agent. Clofilium phosphate significantly prolongs the action potential duration and effective refractory period of canine cardiac Purkinje fibers, increases the ventricular fibrillation threshold, reduces the risk of reentrant arrhythmias, and enables spontaneous conversion of some ventricular fibrillation episodes to sinus rhythm. Clofilium phosphate is applicable to research related to ventricular fibrillation, arrhythmias, and ventricular tachyarrhythmias.

Clodazon (AW 142446) is an antidepressive agent.

Clathrin-IN-5 (Compound 9) is a Clathrin N-terminal domain-Amphiphysin protein-protein interaction inhibitor with an IC50 of 2.77 μM. Clathrin-IN-5 inhibits the protein-protein interaction between the clathrin N-terminal domain and amphiphysin. Clathrin-IN-5 inhibits clathrin-mediated endocytosis with an IC50 of 4.6 μM. Clathrin-IN-5 inhibits the GTPase activity of Dynamin I with an IC50 of 29.7 μM.

CK1γ-IN-1 is a non-selective CK1 kinase inhibitor with IC50 values of 780 nM, 570 nM and 990 nM against human CK1γ1, CK1γ2, CK1γ3, respectively. The non-specific binding of CK1γ-IN-1 to multiple kinases enables its application in biological studies of specific CK1γ.

Cizolirtine citrate (E-4018) is an analgesic agent. Cizolirtine citrate has significant analgesic and anti-hyperalgesic action in neuropathic pain models.

Cioteronel is an antiandrogen agent. Cioteronel can be studied in research on androgenetic alopecia.

Ciliatocholate (Ciliatocholic acid) is a nucleoside metabolite.

CI-996 is a potent, selective, orally active angiotensin II (Ang II) type 1 (AT1) receptor antagonist. In rat liver membranes CI-996 displaces specifically bind [125I]Ang II with an IC50 of 0.8 nM. CI-996 has blood pressure-lowering activity.

CI-986 is a dual inhibitor of COX and 5-LOX. CI-986 can prevent the coronary vasoconstriction and the increased production of LTB(4) and LTC(4). CI-986 also has anti-inflammatory and analgesic effects. CI-986 can be used for the researches of inflammation and cardiovascular disease, such as arthritis.

CI-959 is an inhibitor of inflammatory cell activation. CI-959 exhibits anti-inflammatory and anti-allergic activities. CI-959 can inhibit the production of reactive oxygen species by neutrophils, as well as neutrophil adhesion, respiratory burst, and histamine release from mast cells. CI-959 can also inhibit the release of inflammatory mediators such as histamine, leukotrienes, and thromboxane from guinea-pig and human lung tissues, and effectively suppress anti-IgE-induced contractions of human bronchial smooth muscle. CI-959 can be used in the research of inflammatory and allergic diseases, such as asthma.

CHX-3107 is a casein kinase 2 inhibitor .

CHNQD-03301 is an orally active hypoxia-inducible factor-1α (HIF-1α) inhibitor (IC50 = 10.97 nM). CHNQD-03301 promotes the proteasomal degradation of HIF-1α protein, leading to its significant suppression. CHNQD-03301 can reverse HIF accumulation-induced angiogenesis and mitigate the HIF-induced erythrocytosis phenotype in zebrafish models. CHNQD-03301 can be used for the study of colon cancer.

Chlorproethazine hydrochloride is an orally active phenothiazine compound. Chlorproethazine hydrochloride can eliminate spasticity when administered intravenously and also effectively reduce rigidity in decerebrate cats. Chlorproethazine hydrochloride can be used in the research of neurological diseases.

Chenodeoxycholyl-putrescine is a polyamine bile amidate.

CGP 47645 is a long-acting nonsteroidal aromatase inhibitor. CGP 47645 can significantly affect testicular function. CGP 47645 can be used to study the physiological role of estrogen in regulating testicular function.

cGAS-IN-6 (14) is a cGAS inhibitor. cGAS-IN-6’s core structure is a fused imidazole ring system. cGAS-IN-6 can be used for research on autoimmune conditions.

CDK7-IN-33 (formula Ⅰ) is a pyrimidine derivative and also a CDK7 kinase inhibitor. CDK7-IN-33 is applicable to the research of cancer, inflammation, cardiovascular diseases, infectious diseases, immune diseases and metabolic diseases.

CDK4-IN-4 (example 30) is a selective CDK4 inhibitor (IC50＜10 nM) that can be used in cancer research.

CDK2-IN-55 (Compound 12c) is a CDK2 inhibitor with an IC50 value of 4.7 nM. CDK2-IN-55 also has a strong inhibitory effect on CDK1 (IC50 = 26.3 nM), moderate inhibitory effects on Aurora A (IC50 = 92.0 nM) and CDK9 (IC50 = 288 nM), and very weak inhibitory activities on CDK4, CDK6, DYRK1A, and GSK3β (IC50 > 1000 nM). CDK2-IN-55 shows strong anti-proliferative activity against various cancer cell lines, inducing cell cycle arrest and apoptosis. CDK2-IN-55 can be used for research on colorectal cancer, lung cancer, and cervical cancer.

CDK2-IN-54 (Formula I) is a CDK2 inhibitor. CDK2-IN-54 can be used in cancer research such as triple-negative breast cancer, ovarian cancer, bladder cancer, and uterine cancer.

CDK2-IN-52 (Compound Cpb No 39) is a selective cyclin-dependent kinase 2 (CDK2) inhibitor with a DC50 value of 1-10 nM. CDK2-IN-52 induces cell cycle arrest and suppresses tumor cell proliferation. CDK2-IN-52 is promising for research of CDK2-overexpressing malignancies such as breast and ovarian cancers.

CDK12 ligand-3 is a molecular glucose degrading agent that targets the CDK12 protein (DC50 = 35 nM). CDK12 ligand-3 degrades CDK12, CDK13 and their regulatory subunit Cyclin K in a concentration dependent manner, and inhibits RNA polymerase II CTD (Ser2) phosphorylation. CDK12 ligand-3 exhibits potent anti proliferative activity against Jurkat cells. CDK12 ligand-3 can be used for research on cancers such as leukemia.

CDH11-IN-1 is a CDH11 inhibitor. CDH11-IN-1 regulates CDH11-mediated biological pathways. CDH11-IN-1 can be used for research on cancer and rheumatoid arthritis.

CDA-IN-5 (Compound M-09) is a Chitin deacetylase inhibitor with a Ki of 27.5 μM against PstCDA. CDA-IN-5 is an antifungal agent. CDA-IN-5 can inhibit infection by Rhizoctonia solani, Pyricularia oryzae, and Botrytis cinerea and exhibits moderate control efficacy against rice sheath blight.

CD38-IN-5 (compound 1) is a CD38 inhibitor that selectively inhibits CD38 hydrolase with an IC50 of 4.0 μM. CD38-IN-5 does not inhibits CD38 cyclase. CD38-IN-5 is highly effective at promoting NK cell-mediated tumor toxicity. CD38-IN-5 increases NADH+ and IFNγ levels in activated PBMCs. CD38-IN-5 can be used for the study of cancer.